Neuroendocrine tumours: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

EU-13 is a filter, not a ranking: it only narrows the list.

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Updated 22 Sept 2026

  “Closed due to slow accrual.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

  NCT04086485· National Cancer Institute (NCI)· Source

• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 117
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 49
• Metabolomics 20
• Mass Spectrometry 4
• Flow Cytometry 55
• Immunohistochemistry 185
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 116
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 199
• Machine Learning 51
• Deep Learning 53
• Cohort Studies 79
• Genome-Wide Association Study 12

• Pre-treatment machine learning prediction of local failure and time to local failure after Gamma Knife radiosurgery for radioresistant brain metastases.

  J Neurooncol, Nov 2026

• Burden of malignant melanoma among the elderly population in East Asia from 1990 to 2023 and machine learning projection to 2040.

  PLoS One, Sept 2026

• Predicting Targeted and Immunotherapeutic Response Outcomes in Melanoma With Single-Cell Raman Spectroscopy and Artificial Intelligence.

  JCO Precis Oncol, Sept 2026

• Explainable AI-Assisted Label-Free Raman Biosensing Reveals Therapy-Associated Spectral Signatures in Melanoma Tumors.

  Biosensors (Basel), Sept 2026

• Machine learning for functional outcome prediction after vestibular schwannoma surgery: a systematic review and diagnostic test accuracy meta-analysis.

  J Neurooncol, Aug 2026

• A multiscale geospatial analysis integrating explainable machine learning to characterize spatial disparities in melanoma mortality associated with environmental justice and healthcare access in the contiguous United States.

  Front Public Health, Aug 2026

• Development of a novel RNA modification-based risk model to predict prognosis and immunotherapy response in melanoma using machine learning.

  J Cancer Res Clin Oncol, Aug 2026

• A dual-validated machine learning model for predicting 3-year mortality in atypical pulmonary carcinoid, a rare neuroendocrine tumor.

  Front Endocrinol (Lausanne), Aug 2026

• FFixR: a machine learning framework for accurate somatic mutation calling from FFPE RNA-seq data in cancer.

  Bioinformatics, Jul 2026

• Artificial intelligence in pheochromocytoma and paraganglioma: from diagnostic modeling to clinically integrated decision support systems.

  Endocr Relat Cancer, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.